SCHEMBL3201465

SCHEMBL3201465

Oc1ccc2c(c1)COc1c-2cc2ccc(O)cc2c1-c1ccncc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38
ESRRB O95718 6/20 0.37
ESRRA P11474 6/20 0.37
CYP17A1 P05093 5/20 0.37
CYP3A4 P08684 5/20 0.37
CYP11B1 P15538 5/20 0.37
CYP11B2 P19099 5/20 0.37
PRF1 P14222 1/20 0.35
PDGFRB P09619 1/20 0.35
PDGFRA P16234 1/20 0.35
DYRK1A Q13627 1/20 0.34
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
ALOX5 P09917 1/20 0.34
CYP19A1 P11511 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3188483 0.88 ALOX5 (0.39) HSD17B1HSD17B2ESRRBESRRACYP17A1
SCHEMBL3190566 0.86 ESRRB (0.47) ESRRBESRRACYP17A1CYP3A4CYP11B1
SCHEMBL3187385 0.86 CYP11B1 (0.53) HSD17B1HSD17B2CYP17A1CYP3A4CYP11B1
SCHEMBL3185517 0.85 ESR1 (0.40) ESRRBESRRACYP17A1CYP3A4CYP11B1
SCHEMBL3203612 0.85 ESR1 (0.40) ESRRBESRRAESR1ESR2
SCHEMBL3195435 0.85 ESRRB (0.39) ESRRBESRRACYP17A1CYP3A4CYP11B1
SCHEMBL3195446 0.84 GPR84 (0.38) ESRRBESRRACYP17A1CYP3A4CYP11B1
SCHEMBL3179995 0.83 CYP17A1 (0.34) ESRRBESRRACYP17A1CYP3A4CYP11B1
SCHEMBL3186636 0.83 CYP17A1 (0.38) ESRRBESRRACYP17A1CYP3A4CYP11B1
SCHEMBL3200415 0.83 ESR1 (0.43) PIK3CAPIK3CBESRRBESRRACYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157492-B2 Dibenzo chromene derivatives and their use as ERβ selective ligands WYETH (US) 2007-01-02 US claimed
EP-1718630-A1 DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ER&bgr; SELECTIVE LIGANDS Wyeth a Corporation of the State of Delaware (US) 2006-11-08 EP claimed
US-20050234074-A1 Dibenzo chromene derivatives and their use as ERbeta selective ligands WYETH (US) 2005-10-20 US claimed
WO-2005082880-A1 DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ERβ SELECTIVE LIGANDS WYETH (US) 2005-09-09 WO claimed
US-7671084-B2 Dibenzo chromene derivatives and their use as ERβ selective ligands WYETH (US) 2010-03-02 US disclosed
US-20070049605-A1 Dibenzo chromene derivatives and their use as ERbeta selective ligands WYETH (US) 2007-03-01 US disclosed
US-7157492-B2 Dibenzo chromene derivatives and their use as ERβ selective ligands WYETH (US) 2007-01-02 US disclosed
EP-1718630-A1 DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ER&bgr; SELECTIVE LIGANDS Wyeth a Corporation of the State of Delaware (US) 2006-11-08 EP disclosed
US-20050234074-A1 Dibenzo chromene derivatives and their use as ERbeta selective ligands WYETH (US) 2005-10-20 US disclosed
WO-2005082880-A1 DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ERβ SELECTIVE LIGANDS WYETH (US) 2005-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234074-A1 Dibenzo chromene derivatives and their use as ERbeta selective ligands ESR2, ESR1, ESRRB PIK3CA 1523/4885PIK3CB 2518/4885HSD17B1 152/4885
US-20070049605-A1 Dibenzo chromene derivatives and their use as ERbeta selective ligands ESR2, ESR1, ESRRA PIK3CA 1285/4885PIK3CB 2301/4885HSD17B1 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.